Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib

Purpose To compare the effectiveness of octreotide/everolimus vs. sunitinib for the systemic treatment of recurrent aggressive meningiomas. Methods 31 patients with recurrent or refractory WHO II or WHO III meningiomas were examined in two reference centers in Colombia. Patients who had systemic tre...

Full description

Autores:
Cardona-Mendoza, Andrés Felipe
Ruíz-Patiño, Alejandro
Zatarain Barrón, Zyanya Lucia
Hakim, Fernando
Jiménez, Enrique
Ramón, Juan Fernando
Useche, Nicolás
Bermúdez, Sonia
Pineda, Diego
Cifuentes, Hernando
Rojas Puentes, Leonardo
Ricaurte, Luisa
Pino, Luis Eduardo
Balaña, Carmen
Arrieta, Oscar
Mejía Cordovez, Juan Armando
Tipo de recurso:
Fecha de publicación:
2018
Institución:
Universidad El Bosque
Repositorio:
Repositorio U. El Bosque
Idioma:
eng
OAI Identifier:
oai:repositorio.unbosque.edu.co:20.500.12495/1669
Acceso en línea:
http://hdl.handle.net/20.500.12495/1669
https://doi.org/10.1371/journal.pone.0217340
Palabra clave:
Neoplasias de tejido nervioso
Compuestos orgánicos
Conformación molecular
Rights
License
Attribution 4.0 International
id UNBOSQUE2_f4aa835cc23c14faf1ecdd413b2462f0
oai_identifier_str oai:repositorio.unbosque.edu.co:20.500.12495/1669
network_acronym_str UNBOSQUE2
network_name_str Repositorio U. El Bosque
repository_id_str
dc.title.spa.fl_str_mv Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib
title Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib
spellingShingle Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib
Neoplasias de tejido nervioso
Compuestos orgánicos
Conformación molecular
title_short Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib
title_full Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib
title_fullStr Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib
title_full_unstemmed Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib
title_sort Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib
dc.creator.fl_str_mv Cardona-Mendoza, Andrés Felipe
Ruíz-Patiño, Alejandro
Zatarain Barrón, Zyanya Lucia
Hakim, Fernando
Jiménez, Enrique
Ramón, Juan Fernando
Useche, Nicolás
Bermúdez, Sonia
Pineda, Diego
Cifuentes, Hernando
Rojas Puentes, Leonardo
Ricaurte, Luisa
Pino, Luis Eduardo
Balaña, Carmen
Arrieta, Oscar
Mejía Cordovez, Juan Armando
dc.contributor.author.none.fl_str_mv Cardona-Mendoza, Andrés Felipe
Ruíz-Patiño, Alejandro
Zatarain Barrón, Zyanya Lucia
Hakim, Fernando
Jiménez, Enrique
Ramón, Juan Fernando
Useche, Nicolás
Bermúdez, Sonia
Pineda, Diego
Cifuentes, Hernando
Rojas Puentes, Leonardo
Ricaurte, Luisa
Pino, Luis Eduardo
Balaña, Carmen
Arrieta, Oscar
Mejía Cordovez, Juan Armando
dc.contributor.orcid.none.fl_str_mv Cardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
Rojas Puentes, Leonardo [0000-0002-7865-5424]
Ruíz-Patiño, Alejandro [0000-0003-1274-9273]
dc.subject.decs.spa.fl_str_mv Neoplasias de tejido nervioso
Compuestos orgánicos
Conformación molecular
topic Neoplasias de tejido nervioso
Compuestos orgánicos
Conformación molecular
description Purpose To compare the effectiveness of octreotide/everolimus vs. sunitinib for the systemic treatment of recurrent aggressive meningiomas. Methods 31 patients with recurrent or refractory WHO II or WHO III meningiomas were examined in two reference centers in Colombia. Patients who had systemic treatment (sunitinib, everolimus/octreotide) and a complete follow-up were included. Overall survival (OS), progression-free survival (PFS) and toxicities were evaluated. Additionally, tissue samples were examined for PDGFRβ and VEGFR2, their expression was correlated with outcomes. Results Twenty-two patients (72%) were female with a median age of 55 years (SD±15.3). The most prevalent histology was anaplastic meningioma in 20 patients (65%) with 48% of patients suffering from three previous relapses before the start of systemic treatment. A total of 14 patients received combination therapy with octreotide/everolimus, 11 received sunitinib and the remaining 6 received other second-line agents. Median OS was 37.3 months (95%CI 28.5–42.1) and the PFS during the treatment with everolimus/octreotide (EO) and sunitinib (Su) was 12.1 months (95%CI 9.2–21.1) and 9.1 months (95%CI 6.8–16.8); p = 0.43), respectively. The OS of the group treated with the EO→Su→Bev sequence (1st/2nd/3rd line) was 6.5 months longer than the Su→EO→Bev sequence (36.0 vs. 29.5 months) (p = 0.0001). When analyzing molecular markers, the positive PDGFRβ and negative VEGFR2 expression were associated with longer survival both in OS and PFS. Conclusion Sunitinib and octreotide/everolimus have similar efficacy and safety in the systemic management of refractory meningioma. VEGFR2 and PDGFRβ expression are associated with better outcomes.
publishDate 2018
dc.date.issued.none.fl_str_mv 2018
dc.date.accessioned.none.fl_str_mv 2019-09-11T19:59:35Z
dc.date.available.none.fl_str_mv 2019-09-11T19:59:35Z
dc.type.spa.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.local.spa.fl_str_mv artículo
dc.identifier.issn.none.fl_str_mv 1932-6203
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12495/1669
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1371/journal.pone.0217340
dc.identifier.instname.spa.fl_str_mv instname:Universidad El Bosque
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourl.none.fl_str_mv repourl:https://repositorio.unbosque.edu.co
identifier_str_mv 1932-6203
instname:Universidad El Bosque
reponame:Repositorio Institucional Universidad El Bosque
repourl:https://repositorio.unbosque.edu.co
url http://hdl.handle.net/20.500.12495/1669
https://doi.org/10.1371/journal.pone.0217340
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.ispartofseries.spa.fl_str_mv Plos ONE, 1932-6203, Vol. 14, Nro. 16, 2018, p. 1-13
dc.relation.uri.none.fl_str_mv https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0217340
dc.rights.*.fl_str_mv Attribution 4.0 International
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by/4.0/
dc.rights.local.spa.fl_str_mv Acceso abierto
dc.rights.accessrights.none.fl_str_mv http://purl.org/coar/access_right/c_abf359
dc.rights.creativecommons.none.fl_str_mv 2019
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Acceso abierto
http://purl.org/coar/access_right/c_abf359
2019
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Springer
dc.publisher.journal.spa.fl_str_mv Plos ONE
institution Universidad El Bosque
bitstream.url.fl_str_mv http://18.204.144.38/bitstreams/3907223f-8451-432f-8ac2-40c5c133cf9a/download
http://18.204.144.38/bitstreams/3e4880e0-7735-434e-91f4-8302b981716f/download
http://18.204.144.38/bitstreams/74c40204-bab4-45f6-9703-d5b751280ed6/download
http://18.204.144.38/bitstreams/b9503268-619e-4df4-beff-05b6c25318e3/download
http://18.204.144.38/bitstreams/a246d226-5b58-43c2-b7b6-1c13e7952f05/download
bitstream.checksum.fl_str_mv 863fb1f110076b266bb6cc4e4194047d
8a4605be74aa9ea9d79846c1fba20a33
0175ea4a2d4caec4bbcc37e300941108
02abee04e740e8ac2d5667e2cc1753ec
5c649a013b2501f01170244736907a39
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv DSpace Pre-instalado Biteca S.A.S
repository.mail.fl_str_mv bibliotecas@biteca.com
_version_ 1808397359985459200
spelling Cardona-Mendoza, Andrés FelipeRuíz-Patiño, AlejandroZatarain Barrón, Zyanya LuciaHakim, FernandoJiménez, EnriqueRamón, Juan FernandoUseche, NicolásBermúdez, SoniaPineda, DiegoCifuentes, HernandoRojas Puentes, LeonardoRicaurte, LuisaPino, Luis EduardoBalaña, CarmenArrieta, OscarMejía Cordovez, Juan ArmandoCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]Rojas Puentes, Leonardo [0000-0002-7865-5424]Ruíz-Patiño, Alejandro [0000-0003-1274-9273]2019-09-11T19:59:35Z2019-09-11T19:59:35Z20181932-6203http://hdl.handle.net/20.500.12495/1669https://doi.org/10.1371/journal.pone.0217340instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coapplication/pdfengSpringerPlos ONEPlos ONE, 1932-6203, Vol. 14, Nro. 16, 2018, p. 1-13https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0217340Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Acceso abiertohttp://purl.org/coar/access_right/c_abf3592019http://purl.org/coar/access_right/c_abf2Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinibarticleartículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Neoplasias de tejido nerviosoCompuestos orgánicosConformación molecularPurpose To compare the effectiveness of octreotide/everolimus vs. sunitinib for the systemic treatment of recurrent aggressive meningiomas. Methods 31 patients with recurrent or refractory WHO II or WHO III meningiomas were examined in two reference centers in Colombia. Patients who had systemic treatment (sunitinib, everolimus/octreotide) and a complete follow-up were included. Overall survival (OS), progression-free survival (PFS) and toxicities were evaluated. Additionally, tissue samples were examined for PDGFRβ and VEGFR2, their expression was correlated with outcomes. Results Twenty-two patients (72%) were female with a median age of 55 years (SD±15.3). The most prevalent histology was anaplastic meningioma in 20 patients (65%) with 48% of patients suffering from three previous relapses before the start of systemic treatment. A total of 14 patients received combination therapy with octreotide/everolimus, 11 received sunitinib and the remaining 6 received other second-line agents. Median OS was 37.3 months (95%CI 28.5–42.1) and the PFS during the treatment with everolimus/octreotide (EO) and sunitinib (Su) was 12.1 months (95%CI 9.2–21.1) and 9.1 months (95%CI 6.8–16.8); p = 0.43), respectively. The OS of the group treated with the EO→Su→Bev sequence (1st/2nd/3rd line) was 6.5 months longer than the Su→EO→Bev sequence (36.0 vs. 29.5 months) (p = 0.0001). When analyzing molecular markers, the positive PDGFRβ and negative VEGFR2 expression were associated with longer survival both in OS and PFS. Conclusion Sunitinib and octreotide/everolimus have similar efficacy and safety in the systemic management of refractory meningioma. VEGFR2 and PDGFRβ expression are associated with better outcomes.ORIGINALCardona A.F., Ruiz-Patiño A., Zatarain-Barrón Z.L..pdfCardona A.F., Ruiz-Patiño A., Zatarain-Barrón Z.L..pdfapplication/pdf1111330http://18.204.144.38/bitstreams/3907223f-8451-432f-8ac2-40c5c133cf9a/download863fb1f110076b266bb6cc4e4194047dMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://18.204.144.38/bitstreams/3e4880e0-7735-434e-91f4-8302b981716f/download8a4605be74aa9ea9d79846c1fba20a33MD53CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8908http://18.204.144.38/bitstreams/74c40204-bab4-45f6-9703-d5b751280ed6/download0175ea4a2d4caec4bbcc37e300941108MD52THUMBNAILCardona A.F., Ruiz-Patiño A., Zatarain-Barrón Z.L..pdf.jpgCardona A.F., Ruiz-Patiño A., Zatarain-Barrón Z.L..pdf.jpgIM Thumbnailimage/jpeg12982http://18.204.144.38/bitstreams/b9503268-619e-4df4-beff-05b6c25318e3/download02abee04e740e8ac2d5667e2cc1753ecMD54TEXTCardona A.F., Ruiz-Patiño A., Zatarain-Barrón Z.L..pdf.txtCardona A.F., Ruiz-Patiño A., Zatarain-Barrón Z.L..pdf.txtExtracted texttext/plain47528http://18.204.144.38/bitstreams/a246d226-5b58-43c2-b7b6-1c13e7952f05/download5c649a013b2501f01170244736907a39MD5520.500.12495/1669oai:18.204.144.38:20.500.12495/16692024-02-06 22:05:01.833http://creativecommons.org/licenses/by/4.0/Attribution 4.0 Internationalopen.accesshttp://18.204.144.38DSpace Pre-instalado Biteca S.A.Sbibliotecas@biteca.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